Intelligent Bio Solutions Scales Manufacturing to Fuel Growth and U.S. Ambitions

Intelligent Bio Solutions quadruples production capacity via a new partnership, cuts costs over 40%, and boosts gross margin 20 points to fuel U.S. market entry plans.

Intelligent Bio Solutions Inc. has announced significant operational advancements, centered on a major expansion of its manufacturing capacity for drug testing technology. The company's latest strategic moves, including a new production partnership and strengthened vertical integration, are designed to enhance profitability and accelerate its planned entry into the United States market.

Strategic Manufacturing Deal Drives Efficiency

A key development is a recently confirmed manufacturing partnership with Syrma Johari MedTech. The collaboration has already yielded its first shipment of drug testing readers. This alliance is expected to quadruple Intelligent Bio Solutions' production capacity. Furthermore, by strategically shifting its manufacturing operations, the company anticipates reducing annual costs by more than 40%.

Management projects that these operational efficiencies will boost the gross margin by approximately 20 percentage points annually. In a parallel move to increase control over its supply chain, the company has doubled its in-house production of test strips. This step not only enhances vertical integration but also speeds up research and development efforts for expanded test cartridge offerings.

Financial Performance and Commercial Expansion

The company's growth trajectory is supported by concrete financial results. For the second fiscal quarter, revenue increased by 48% year-over-year to $896,774. Sales of the reader devices were particularly strong, surging by 104%. For the first half of fiscal year 2026, total revenue reached $2.01 million, while the gross margin improved substantially from 39% to 49%.

On the commercial front, Intelligent Bio Solutions has secured a new partnership with Bouygues UK. The contractor will deploy the company's fingerprint-based drug testing technology across 13 project sites in the United Kingdom. Analyses indicate the technology offers considerable cost advantages over traditional third-party testing methods, laying the groundwork for a potential global rollout within the construction group.

Capital Raise Supports U.S. Market Entry Plans

These strategic initiatives are backed by a strengthened balance sheet. In early January, the company completed a private placement, receiving net proceeds of $9.4 million. These funds are earmarked primarily for working capital and to finance the clinical validation process required for regulatory approval.

The clinical validation is a critical step toward achieving 510(k) clearance from the U.S. Food and Drug Administration (FDA). Securing this FDA approval remains a central pillar of Intelligent Bio Solutions' strategy to facilitate a timely entry into the substantial U.S. market.